You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Development of a Scalable, Cloud-Based Microbiome Big Data Analytics System
SBC: WHOLE BIOME INC. Topic: 400The human microbiome has emerged as a hitherto unknown causal factor in a number of disease ranging from cancer cardiovascular disease and obesity To understand the biochemical mechanisms of the human microbiome in these diseases researchers must be able to store biochemical pathway transcriptomic and metabolomic datasets in a coherent and compatible form We propose to construct a cloud ba ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Maximizing cancer synthetic lethality using dual PI-3K/PARP inhibitors
SBC: SignalRx Pharmaceuticals Inc. Topic: NCIPARP inhibitors PARPi are particularly efficacious in tumors deficient in the BRCA tumor suppressor genes but of limited activity in BRCA competent tumors There is an unmet medical need to develop targeted therapeutic agents which will augment PARPi activity for BRCA wild type cancers and to increase chemo radiosensitivity in these malignancies BRCA proteins are essential components ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Development of Alkontrol herbal for Treating Alcohol Abuse
SBC: NATURAL PHARMACIA INTERNATIONAL, INC. Topic: NIAAADESCRIPTION provided by applicant This application for a Fast Track STTR award represents a collaboration between Natural Pharmacia International Inc NPI and McLean Hospital to initiate steps toward commercializing a isoflavone botanical product for treating alcoholism Excessive use of alcohol accounts for much of the public health burden related to alcohol use disorders including fetal a ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Small, high-affinity ligands for array tomography
SBC: ARATOME, LLC Topic: 101DESCRIPTION provided by applicant Neurodegenerative diseases are among the most expensive disruptive and least well treated of human maladies arguably because they are not well understood Array tomography AT is a method for tissue imaging with resolution in all three dimensions sufficient to resolve individual synapses and provide quantitative characterization ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
The Allogeneic Heart Stem Cell Trial in Hypoplastic Left Heart Syndrome Patients
SBC: CAPRICOR, INC. Topic: NHLBIDESCRIPTION provided by applicant One of the most complex forms of congenital heart disease hypoplastic left heart syndrome HLHS affects an average of in every newborns with a mortality rate of up to percent during the first year of life The overall goal f our research is to develop safe and effective ways to improve short term and long term survival rates in babies born with HL ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Personalized dosing of dichloroacetate for the treatment of rare and common diseases
SBC: Medosome Biotec, LLC Topic: NICHDABSTRACT SUMMARY Pyruvate dehydrogenase complex PDC deficiency PDCD is a rare disease of mitochondrial energy failure in which the life of expectancy of affected children is severely truncated Treatment of PDCD remains a serious unmet challenge There has never been a controlled trial of any intervention for PDCD thus there is no proven therapy for affected patients Dichloroacetate DCA ...
STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health -
Therapeutics for inflammatory bowel disease from the microbiome
SBC: SYMBIOTIX BIOTHERAPIES, INC. Topic: 300PROJECT SUMMARY ABSTRACT Interactions between the gut microbiome and the immune system have been linked to inflammatory bowel disease IBD IBD is a chronic and progressive gastrointestinal disease characterized by uncontrolled activation of the intestinal immune system resulting in severe medical complications affecting over million patients in the United States It is a disease of high u ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Modulation of the Innate Immune Response by Fisetin Derivatives for the Treatment of AD
SBC: VIROGENICS, INC. Topic: NIAIDDESCRIPTION provided by applicant There are currently no drugs or other therapeutic interventions that can reverse or halt the progression of Alzheimerandapos s disease AD Age is by far the greatest risk factor for AD and it is known from studies in both mice and humans that neuroinflammation is increased with old age and to an even greater extent in AD Therefore a drug that could reduce ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Testing of a Novel Flow Diverting Stent for Treating Intracranial Aneurysms
SBC: NeuroSigma, Inc. Topic: 101DESCRIPTIONprovided by applicantThe purpose of this project is to develop an improvedminimally invasive treatment for intracranial aneurysmsIntracranial aneurysms are spherical outpouchings of blood vessels in the head that result from weakness in the vessel wallUnruptured aneurysms are present in approximatelyof the general populationand rupture can be devastating with a high morbidity and mortal ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health -
Developing Therapeutics That Target RAD To Treat Leukemia and Lymphoma
SBC: Cyteir Therapeutics, Inc. Topic: NCIDESCRIPTION provided by applicant Genomic instability is a hallmark of cancer and represents a targetable vulnerability yet is underdeveloped as a therapeutic area The central goal of this Phase program is to complete the early preclinical development of a new class of new cancer therapeutics that uniquely target RAD delivering effective cancer cell selective therapy in subsets of bioma ...
STTR Phase II 2016 Department of Health and Human ServicesNational Institutes of Health